Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.36 |
| ▸ | MPL | P40238 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4511441 | 0.86 | PTGES (0.40) | ESR1PTGESMPLLMNACA2 | |
| SCHEMBL4503529 | 0.84 | ESR1 (0.41) | ESR1PTGESMPLLMNACA2 | |
| SCHEMBL4505853 | 0.83 | PTGES (0.46) | ESR1PTGESMPLLMNAHSD17B1 | |
| SCHEMBL4506540 | 0.82 | PTGES (0.40) | ESR1PTGESMPLHSD17B1HSD17B2 | |
| SCHEMBL4510070 | 0.81 | PTGES (0.39) | ESR1PTGESMPLLMNANPC1 | |
| SCHEMBL4517757 | 0.80 | ESR1 (0.47) | ESR1PTGESLMNAKAT6ACA2 | |
| SCHEMBL4494785 | 0.80 | ESR1 (0.49) | ESR1PTGESMPLLMNACA2 | |
| SCHEMBL4497549 | 0.80 | PTGES (0.35) | ESR1TRPV1PTGESMPLLMNA | |
| SCHEMBL4510732 | 0.79 | PTGES2 (0.41) | ESR1TRPV1PTGESMPLLMNA | |
| SCHEMBL4508410 | 0.78 | PTGES (0.41) | ESR1PTGESMPLLMNACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090234014-A1 | Naphthalene-Disulfonamides Useful for the Treatment of Inflammation | BIOLIPOX AB (SE) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090234014-A1 | Naphthalene-Disulfonamides Useful for the Treatment of Inflammation | AREG, PRSS12, CXCL8 | ESR1 1760/4885TRPV1 1914/4885PTGES 41/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.